Compare Patterson-UTI Energy Inc. Common Stock (PTEN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Patterson-UTI Energy Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Patterson-UTI Energy Inc. Common Stock trades at $11.6 (market cap $4.39B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Patterson-UTI Energy Inc. Common Stock is the larger of the two by market cap, and Patterson-UTI Energy Inc. Common Stock pays a 3.48% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Patterson-UTI Energy Inc. Common Stock for 3 Days and Tango Therapeutics Inc. for 0 Days on average.
| PTEN | TNGX | |
|---|---|---|
Market Cap | $4.39B | $3.75B |
Volume | 4,811,496 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $13.15 | $32.90 |
52-Week Low | $5.41 | $7.50 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $5.47B | $2.77B |
Dividend Yield | 3.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Patterson-UTI Energy (PTEN) trades at $11.52, up 1.68% today, with a neutral technical signal. The stock shows strong cash flow from operations at $961.22M for 2025, but net income remains negative at -$93.64M. Recent earnings beats and an upcoming Q3 2026 report on October 29, 2026, highlight operational momentum, supported by an average of 103 drilling rigs in September 2026. Analyst consensus is bullish with a $13.38 price target, indicating a 16% upside.
The outlook is cautiously optimistic due to earnings consistency and positive analyst sentiment, but risks include persistent net losses, exposure to oil price volatility, and competitive pressures. Upside potential hinges on sustained rig demand and profitability improvements, while downside risks stem from macroeconomic headwinds affecting energy sectors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Patterson-UTI Energy Inc. Common Stock
Patterson-UTI Energy provides drilling, completion, and other oilfield services for oil and gas producers in the United States.
Read more on PTEN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
